You are here

Vision-QOL-CAT: A Functional Health CAT for those with Visual Disorders

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43EY021390-01
Agency Tracking Number: R43EY021390
Amount: $98,632.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NEI
Solicitation Number: PA10-050
Timeline
Solicitation Year: 2011
Award Year: 2011
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1 INNOVATION DR, STE 400
WORCESTER, MA 01605-
United States
DUNS: 831513820
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN WARE
 (508) 363-1236
 john.ware@jwrginc.com
Business Contact
 JAMES DEWEY
Phone: (508) 363-1236
Email: james.dewey@jwrginc.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): With the aging of the population, vision loss is a growing public health problem affecting more than 3 million Americans. The impact of eye disease on health-related quality of life (HRQOL) and the benefits of new treatments are not well understood and have not been compared with those for other medical conditions. Although self-assessment tools for measuring the impact of visual disorders (e.g., VF-14, ADVS, NEI-VFQ) are available, the development of instruments that are more efficient in measuring the impact of visual disorders over a wide range of functional health levels and comprehensive domains has not kept pace with advancements achieved for generic HRQOL tools. We propose to use Item Response Theory (IRT) and Computerized Adaptive Testing (CAT) techniques, proven in studies of other conditions, to build a more efficient Patient-Reported Outcomes (PRO) instrument (VISION-QOL-CAT) to measure the impact of adult visual disorders. CATs tailor questions administered toeach individual for each domain, thereby increasing precision and range of measurement without increasing respondent burden. Our Phase I aims are to: (1) construct and administer (N=300) new vision-specific HRQOL item banks to measure the impact of visualdisorders and perform preliminary psychometric and clinical evaluations of their usefulness; (2) develop a comprehensive (vision-specific and generic HRQOL) and flexible VISION-QOL-CAT prototype solution; and (3) pilot test (N=100) the prototype tool in comparison with existing legacy full-length static questionnaires in a vision clinic setting. We will partner with the UMass Memorial Eye Center in fielding surveys of adult patients differing in severity of vision loss, including both wet and dry types of age- related macular degeneration. The product of Phase I will be a prototype comprehensive VISION-QOL- CAT with preliminary evidence regarding feasibility, acceptability, and empirical performance in comparison with static generic and vision-specific HRQOL tools. In Phase II, the system will be expanded (content) and improved (administration efficiency, reliable range, psychometric and utility index scoring options, patient and provider reports, user-friendly documentation) and further evaluated inboth qualitative and quantitative terms (psychometrics, clinical responsiveness) across different platforms (e.g., iPod/iPhone/iPad, Internet-based, PC, telephone IVR), and normed in general populations and among those with eye disease. By lowering data collection costs, reducing response burden, eliminating ceiling and floor effects and increasing the precision of individual scores, the HRQOL outcomes observed in clinical research may be monitored and managed to improve care for adults with visual disorders. PUBLIC HEALTH RELEVANCE: The VISION-QOL-CAT is a new tool for assessing the impact of visual disorders on quality of life (QOL). The prototype study will provide preliminary evidence regarding feasibility and acceptability of the new tool ina clinical setting. The tool's performance will be compared to other patient-reported QOL tools for measuring generic and vision-specific health outcomes. More practical and useful tools will make it possible to consider functional health and well-being in making treatment decisions and in enabling patients to play a more active role in managing their eye disease.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government